Comet Therapeutics is the leader in CoEnzyme A (CoA) science and intermediate metabolism. Our proprietary CoMET Platform is the foundation of a growing pipeline of next-generation therapeutics to treat conditions in which dysregulated CoA plays a role. Utilizing this science and forging innovative partnerships, Comet aspires to develop and commercialize treatments for patients suffering from metabolic, neurological and immunological disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/20/19 | $28,500,000 | Series A |
Canaan Partners INKEF Capital Sofinnova Partners | undisclosed |
